Head & Neck


CIRB #H-37278/NRG #HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

CIRB #H-32379/ RTOG #R1216: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck (temporary closure)


CIRB #H-33148/NRG #HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Salivary Gland:

IRB #H-35696/RTOG #R1008: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Second Line:

IRB #H-38438/ DFCI/BMS #17-411: Adjuvant Nivolumab and Lirilumab in Patients with Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck

IRB #H-38134/ RTOG Foundation #R3507: A Randomized phase II study of Pembrolizumab (KEYTRUDA®) plus Stereotactic Re-Irradiation versus SBRT alone for Locoregionally recurrent or second primary head and neck Carcinoma (pending)